(InSilico Medicine, Inc.) Insilico Medicine today announced a research collaboration with LongeVC, a venture fund dedicated to investing in companies targeting aging and age-related diseases. Insilico Medicine's signaling pathway-based analytical methods and deep learned predictors will be used to evaluate the efficacy, adverse effects, and population-specificity of small molecules, antibodies, gene therapy, and other interventions.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2gwFhBo
No comments:
Post a Comment